Literature DB >> 7538176

A molecular clasp in the human immunodeficiency virus (HIV) type 1 TM protein determines the anti-HIV activity of gp41 derivatives: implication for viral fusion.

C H Chen1, T J Matthews, C B McDanal, D P Bolognesi, M L Greenberg.   

Abstract

We have previously reported that synthetic peptides representing the leucine zipper domain (DP107) and a second putative helical domain (DP178) of human immunodeficiency virus type 1 (HIV-1) gp41 exhibit potent anti-HIV activity. In this study we have used soluble recombinant forms of gp41 to provide evidence that the DP178 peptide and the DP178 region of gp41 associate with a distal site on the gp41 transmembrane protein whose interactive structure is influenced by the leucine zipper (DP107) motif. We also observed that a single coiled-coil-disrupting mutation in the leucine zipper domain transformed the recombinant gp41 protein from an inactive to an active inhibitor of HIV-1 fusion and infectivity, which may be related to that finding. We speculate that this transformation results from liberation of the potent DP178-related sequence from a molecular clasp with a leucine zipper, DP107, determinant. The results are discussed in the context of two distinct conformations for the gp41 molecule and possible involvement of these two domains in structural transitions associated with HIV-1-mediated fusion. The results are also interpreted to suggest that the anti-HIV activity of the various gp41 derivatives (peptides and recombinant proteins) may be due to their ability to form complexes with viral gp41 and interfere with its fusogenic processes.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7538176      PMCID: PMC189094     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  26 in total

1.  Morphometric analysis of recombinant soluble CD4-mediated release of the envelope glycoprotein gp120 from HIV-1.

Authors:  R Kirsh; T K Hart; H Ellens; J Miller; S A Petteway; D M Lambert; J Leary; P J Bugelski
Journal:  AIDS Res Hum Retroviruses       Date:  1990-10       Impact factor: 2.205

2.  Mouse monoclonal antibody 5-21-3 recognizes a contiguous, conformation-dependent epitope and maps to a hydrophilic region in HIV-1 gp41.

Authors:  J C Hunt; S M Desai; J M Casey; T J Bolling; T K Leung; R H Decker; S G Devare; V Sarin
Journal:  AIDS Res Hum Retroviruses       Date:  1990-05       Impact factor: 2.205

Review 3.  Viral and cellular membrane fusion proteins.

Authors:  J M White
Journal:  Annu Rev Physiol       Date:  1990       Impact factor: 19.318

4.  Interaction between the human T-cell lymphotropic virus type IIIB envelope glycoprotein gp120 and the surface antigen CD4: role of carbohydrate in binding and cell fusion.

Authors:  T J Matthews; K J Weinhold; H K Lyerly; A J Langlois; H Wigzell; D P Bolognesi
Journal:  Proc Natl Acad Sci U S A       Date:  1987-08       Impact factor: 11.205

5.  A general model for the transmembrane proteins of HIV and other retroviruses.

Authors:  W R Gallaher; J M Ball; R F Garry; M C Griffin; R C Montelaro
Journal:  AIDS Res Hum Retroviruses       Date:  1989-08       Impact factor: 2.205

6.  Retroviral envelope glycoproteins contain a "leucine zipper"-like repeat.

Authors:  E L Delwart; G Mosialos; T Gilmore
Journal:  AIDS Res Hum Retroviruses       Date:  1990-06       Impact factor: 2.205

7.  Inhibition of HIV-1 infection by a fusion domain binding peptide from the HIV-1 envelope glycoprotein GP41.

Authors:  S Jiang; K Lin; N Strick; A R Neurath
Journal:  Biochem Biophys Res Commun       Date:  1993-09-15       Impact factor: 3.575

8.  Binding of soluble CD4 proteins to human immunodeficiency virus type 1 and infected cells induces release of envelope glycoprotein gp120.

Authors:  T K Hart; R Kirsh; H Ellens; R W Sweet; D M Lambert; S R Petteway; J Leary; P J Bugelski
Journal:  Proc Natl Acad Sci U S A       Date:  1991-03-15       Impact factor: 11.205

9.  Immunodeficiency virus rev trans-activator modulates the expression of the viral regulatory genes.

Authors:  M H Malim; J Hauber; R Fenrick; B R Cullen
Journal:  Nature       Date:  1988-09-08       Impact factor: 49.962

10.  In vitro mutagenesis identifies a region within the envelope gene of the human immunodeficiency virus that is critical for infectivity.

Authors:  R L Willey; D H Smith; L A Lasky; T S Theodore; P L Earl; B Moss; D J Capon; M A Martin
Journal:  J Virol       Date:  1988-01       Impact factor: 5.103

View more
  73 in total

1.  Computational design of D-peptide inhibitors of hepatitis delta antigen dimerization.

Authors:  C D Elkin; H J Zuccola; J M Hogle; D Joseph-McCarthy
Journal:  J Comput Aided Mol Des       Date:  2000-11       Impact factor: 3.686

2.  Modifications that stabilize human immunodeficiency virus envelope glycoprotein trimers in solution.

Authors:  X Yang; L Florin; M Farzan; P Kolchinsky; P D Kwong; J Sodroski; R Wyatt
Journal:  J Virol       Date:  2000-05       Impact factor: 5.103

3.  The role of the third beta strand in gp120 conformation and neutralization sensitivity of the HIV-1 primary isolate DH012.

Authors:  C B Zhu; L Zhu; S Holz-Smith; T J Matthews; C H Chen
Journal:  Proc Natl Acad Sci U S A       Date:  2001-12-04       Impact factor: 11.205

4.  Design of potent inhibitors of HIV-1 entry from the gp41 N-peptide region.

Authors:  D M Eckert; P S Kim
Journal:  Proc Natl Acad Sci U S A       Date:  2001-09-25       Impact factor: 11.205

Review 5.  The energetics of membrane fusion from binding, through hemifusion, pore formation, and pore enlargement.

Authors:  F S Cohen; G B Melikyan
Journal:  J Membr Biol       Date:  2004-05-01       Impact factor: 1.843

6.  Selection with a peptide fusion inhibitor corresponding to the first heptad repeat of HIV-1 gp41 identifies two genetic pathways conferring cross-resistance to peptide fusion inhibitors corresponding to the first and second heptad repeats (HR1 and HR2) of gp41.

Authors:  Wei Wang; Christopher J De Feo; Min Zhuang; Russell Vassell; Carol D Weiss
Journal:  J Virol       Date:  2011-10-12       Impact factor: 5.103

7.  An antibody directed against the fusion peptide of Junin virus envelope glycoprotein GPC inhibits pH-induced membrane fusion.

Authors:  Joanne York; Jody D Berry; Ute Ströher; Qunnu Li; Heinz Feldmann; Min Lu; Meg Trahey; Jack H Nunberg
Journal:  J Virol       Date:  2010-04-14       Impact factor: 5.103

Review 8.  Emerging drug targets for antiretroviral therapy.

Authors:  Jacqueline D Reeves; Andrew J Piefer
Journal:  Drugs       Date:  2005       Impact factor: 9.546

9.  SCH-C (SCH 351125), an orally bioavailable, small molecule antagonist of the chemokine receptor CCR5, is a potent inhibitor of HIV-1 infection in vitro and in vivo.

Authors:  J M Strizki; S Xu; N E Wagner; L Wojcik; J Liu; Y Hou; M Endres; A Palani; S Shapiro; J W Clader; W J Greenlee; J R Tagat; S McCombie; K Cox; A B Fawzi; C C Chou; C Pugliese-Sivo; L Davies; M E Moreno; D D Ho; A Trkola; C A Stoddart; J P Moore; G R Reyes; B M Baroudy
Journal:  Proc Natl Acad Sci U S A       Date:  2001-10-16       Impact factor: 11.205

10.  Structural and functional analysis of interhelical interactions in the human immunodeficiency virus type 1 gp41 envelope glycoprotein by alanine-scanning mutagenesis.

Authors:  M Lu; M O Stoller; S Wang; J Liu; M B Fagan; J H Nunberg
Journal:  J Virol       Date:  2001-11       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.